Biotech entity

Antengene

Company

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ATG-201, the most common co-covered peer. At 6, the average consequence score sits below the same-window beat average of 6.4.

Last mentioned: Mar 20, 2026

Entity pulse

Recent coverage · Antengene

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Antengene

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ATG-201, the most common co-covered peer. At 6, the average consequence score sits below the same-window beat average of 6.4. They are better corroborated than the beat average, carrying 3 original sources each against 2.8 for the same window. Antengene appears in 1 tracked Biotech story from March 20, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Antengene. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Profitability Target

    Antengene aims to achieve its first full year of profitability.

  2. AACR 2026

    Antengene scheduled to present data on next-generation ADCs and TCEs.

  3. 2025 FY Results

    Company announces full-year results and confirms shift toward 2026 profitability.

  4. UCB Partnership

    Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront.

Stories mentioning Antengene 1

Pharma Positive

Antengene Eyes 2026 Profitability Following Landmark TCE Out-Licensing Deal

Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.

3 sources

Antengene is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.